| scholarly article | Q13442814 |
| P50 | author | Mariana Spetea | Q38545108 |
| P2093 | author name string | Lucia Negri | |
| Roberta Lattanzi | |||
| Helmut Schmidhammer | |||
| Silvia Rief | |||
| P2860 | cites work | Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites | Q24611756 |
| Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics | Q24647687 | ||
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction | Q27860958 | ||
| Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? | Q30250027 | ||
| Opiate pharmacology and relief of pain | Q33650564 | ||
| In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function | Q34124185 | ||
| Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships | Q34191006 | ||
| Insights from molecular dynamics simulations to exploit new trends for the development of improved opioid drugs. | Q52315660 | ||
| Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic. | Q55022470 | ||
| Designing Safer Analgesics via μ-Opioid Receptor Pathways | Q43075987 | ||
| Antinociceptive activity of a novel buprenorphine analogue. | Q43987821 | ||
| Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime | Q44345593 | ||
| Novel Opioid Analgesics and Side Effects. | Q44346416 | ||
| Central effect of SNC 80, a selective and systemically active delta-opioid receptor agonist, on gastrointestinal propulsion in the mouse | Q44348395 | ||
| Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency | Q44349793 | ||
| Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists | Q44350044 | ||
| Opioid misuse in gastroenterology and non-opioid management of abdominal pain | Q44350905 | ||
| Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics | Q44351142 | ||
| Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones | Q44351710 | ||
| Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders | Q46563458 | ||
| Abuse-deterrent opioids: an update on current approaches and considerations | Q47274936 | ||
| Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression | Q47669894 | ||
| Comorbid chronic pain and depression: who is at risk? | Q51642005 | ||
| Opioid Receptors. | Q52307702 | ||
| Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities | Q34414232 | ||
| Management of opioid-induced gastrointestinal effects in patients receiving palliative care | Q34523889 | ||
| Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities | Q34939624 | ||
| In vivo opioid receptor heteromerization: where do we stand? | Q34939677 | ||
| A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks | Q35123224 | ||
| Pharmacological investigations of N-substituent variation in morphine and oxymorphone: opioid receptor binding, signaling and antinociceptive activity | Q35185514 | ||
| Inflammatory pain is enhanced in delta opioid receptor-knockout mice | Q35653788 | ||
| Comorbidities in chronic neuropathic pain | Q35680402 | ||
| Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans | Q35769718 | ||
| Opioid receptors: Structural and mechanistic insights into pharmacology and signaling | Q36096058 | ||
| Most recent developments and modifications of 14-alkylamino and 14-alkoxy-4,5-epoxymorphinan derivatives | Q36107406 | ||
| Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches | Q36438816 | ||
| Opioid Peptides: Potential for Drug Development | Q36517233 | ||
| The chemical and pharmacological importance of morphine analogues | Q37128953 | ||
| Dermorphin-related peptides from the skin of Phyllomedusa bicolor and their amidated analogs activate two mu opioid receptor subtypes that modulate antinociception and catalepsy in the rat | Q37140069 | ||
| Opioid complications and side effects. | Q37149936 | ||
| Mu opioids and their receptors: evolution of a concept | Q37236111 | ||
| Opioid receptors: from binding sites to visible molecules in vivo | Q37249017 | ||
| Delta and kappa opioid receptors as suitable drug targets for pain | Q37660843 | ||
| Kappa opioids and the modulation of pain | Q37725698 | ||
| 14-Amino-4,5-epoxymorphinan derivatives and their pharmacological actions | Q37883277 | ||
| Modulation of peripheral sensory neurons by the immune system: implications for pain therapy | Q37942106 | ||
| Recent advances in the development of 14-alkoxy substituted morphinans as potent and safer opioid analgesics. | Q37997853 | ||
| The µ opioid receptor and ligands acting at the µ opioid receptor, as therapeutics and potential therapeutics | Q38085389 | ||
| Hybrid opioid/non-opioid ligands in pain research | Q38085392 | ||
| Molecular physiology of enteric opioid receptors | Q38248063 | ||
| Hopes for the Future of Pain Control | Q38679986 | ||
| Methods used for the study of opioid receptors | Q39167933 | ||
| Targeting multiple opioid receptors - improved analgesics with reduced side effects? | Q39221109 | ||
| Allostery at opioid receptors: modulation with small molecule ligands. | Q39248479 | ||
| Breaking barriers to novel analgesic drug development | Q39360773 | ||
| Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics? | Q39458009 | ||
| Re-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic | Q40529056 | ||
| Highly Potent and Selective New Diphenethylamines Interacting with the κ-Opioid Receptor: Synthesis, Pharmacology, and Structure-Activity Relationships. | Q41722010 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| constipation | Q178436 | ||
| opioid | Q427523 | ||
| P304 | page(s) | 1002 | |
| P577 | publication date | 2018-08-31 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice | |
| P478 | volume | 9 |
Search more.